WHO Head Praises China Response To Coronavirus Emergency; Criticizes “Unnecessary” Trade and Travel Restrictions 03/02/2020 Elaine Ruth Fletcher World Health Organization Director General Dr Tedros Adhanom Ghebreyesus called for “solidarity, solidarity and solidarity” amongst WHO member states to meet the new challenge of a novel coronavirus epidemic – at Monday’s opening of a week-long meeting of WHO’s Executive Board in Geneva. “The rule of the game is solidarity, solidarity, solidarity. But we see […] Continue reading -> What To Watch At The Executive Board: Emergencies, Universal Health Coverage & Eliminating Cervical Cancer 03/02/2020 Grace Ren and Catherine Saez This week’s Executive Board meeting features a heavy agenda of topics, including a review of progress in WHO’s flagship Universal Health Coverage (UHC) initiative; steps taken to confront the burgeoning coronavirus health emergency; and review of a first-ever WHO strategy to eliminate cervical cancer. Debates over the long-term challenges posed by drug resistant pathogens and […] Continue reading -> Emergencies, Cervical Cancer, IP & Innovation Among Highlights Of Member State Consultations Ahead Of WHO Executive Board 09/01/2020 Editorial team Ahead of the upcoming WHO Executive Board meeting 3-8 February, WHO has launched a series of informal consultations this week with member state representatives on key issues that will be coming before the governing body – and ultimately the May meeting of the World Health Assembly (WHA). The detailed consultation agenda, published on the WHO […] Continue reading -> Access To Medicines Postponed; UHC, NTDs & Intellectual Property Feature In Next WHO Executive Board Agenda 14/11/2019 Elaine Ruth Fletcher WHO’s agenda for the next Executive Board (EB) meeting, scheduled for 3-8 February 2020, will see discussions grouped for the first time ever around the three key pillars of the WHO Global Plan of Work for 2019-2023, including expanding health and wellbeing, protection from health emergencies, and universal health coverage to one billion more people. […] Continue reading -> “Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> New Drug Transparency Observatory Launched In France 13/06/2019 David Branigan Following the adoption of the World Health Assembly resolution on the transparency of medicines markets last month, a new civil society group has formed in France to monitor the French government’s implementation of the resolution. L’Observatoire Transparence Médicaments (Drug Transparency Observatory), was launched today in a statement calling on the French government and all countries […] Continue reading -> Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> WHA Strengthens Benefit Sharing System For Pandemic Flu Vaccine Development 03/06/2019 Catherine Saez In a little-publicised move, the WHA last week agreed to close a critical loophole in the WHO Pandemic Influenza Preparedness (PIP) Framework that could have allowed commercial vaccine manufacturers to indirectly make use of biological information about flu strains from another country – without providing that country with any benefits from the vaccines or antivirals […] Continue reading -> WHO’s EB Considers New Ways To Work With NGOs – Some Countries Criticise Activists’ Role At WHA 72 30/05/2019 Elaine Ruth Fletcher In the wake of a World Health Assembly that became a focus of intense activist and social media attention over a WHO resolution on medicines price transparency, member states are now looking at new rules for shaping involvement of NGOs and other “non-state actors” at public WHO meetings. Image Credits: WHO. Continue reading -> Posts navigation Older postsNewer posts
What To Watch At The Executive Board: Emergencies, Universal Health Coverage & Eliminating Cervical Cancer 03/02/2020 Grace Ren and Catherine Saez This week’s Executive Board meeting features a heavy agenda of topics, including a review of progress in WHO’s flagship Universal Health Coverage (UHC) initiative; steps taken to confront the burgeoning coronavirus health emergency; and review of a first-ever WHO strategy to eliminate cervical cancer. Debates over the long-term challenges posed by drug resistant pathogens and […] Continue reading -> Emergencies, Cervical Cancer, IP & Innovation Among Highlights Of Member State Consultations Ahead Of WHO Executive Board 09/01/2020 Editorial team Ahead of the upcoming WHO Executive Board meeting 3-8 February, WHO has launched a series of informal consultations this week with member state representatives on key issues that will be coming before the governing body – and ultimately the May meeting of the World Health Assembly (WHA). The detailed consultation agenda, published on the WHO […] Continue reading -> Access To Medicines Postponed; UHC, NTDs & Intellectual Property Feature In Next WHO Executive Board Agenda 14/11/2019 Elaine Ruth Fletcher WHO’s agenda for the next Executive Board (EB) meeting, scheduled for 3-8 February 2020, will see discussions grouped for the first time ever around the three key pillars of the WHO Global Plan of Work for 2019-2023, including expanding health and wellbeing, protection from health emergencies, and universal health coverage to one billion more people. […] Continue reading -> “Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> New Drug Transparency Observatory Launched In France 13/06/2019 David Branigan Following the adoption of the World Health Assembly resolution on the transparency of medicines markets last month, a new civil society group has formed in France to monitor the French government’s implementation of the resolution. L’Observatoire Transparence Médicaments (Drug Transparency Observatory), was launched today in a statement calling on the French government and all countries […] Continue reading -> Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> WHA Strengthens Benefit Sharing System For Pandemic Flu Vaccine Development 03/06/2019 Catherine Saez In a little-publicised move, the WHA last week agreed to close a critical loophole in the WHO Pandemic Influenza Preparedness (PIP) Framework that could have allowed commercial vaccine manufacturers to indirectly make use of biological information about flu strains from another country – without providing that country with any benefits from the vaccines or antivirals […] Continue reading -> WHO’s EB Considers New Ways To Work With NGOs – Some Countries Criticise Activists’ Role At WHA 72 30/05/2019 Elaine Ruth Fletcher In the wake of a World Health Assembly that became a focus of intense activist and social media attention over a WHO resolution on medicines price transparency, member states are now looking at new rules for shaping involvement of NGOs and other “non-state actors” at public WHO meetings. Image Credits: WHO. Continue reading -> Posts navigation Older postsNewer posts
Emergencies, Cervical Cancer, IP & Innovation Among Highlights Of Member State Consultations Ahead Of WHO Executive Board 09/01/2020 Editorial team Ahead of the upcoming WHO Executive Board meeting 3-8 February, WHO has launched a series of informal consultations this week with member state representatives on key issues that will be coming before the governing body – and ultimately the May meeting of the World Health Assembly (WHA). The detailed consultation agenda, published on the WHO […] Continue reading -> Access To Medicines Postponed; UHC, NTDs & Intellectual Property Feature In Next WHO Executive Board Agenda 14/11/2019 Elaine Ruth Fletcher WHO’s agenda for the next Executive Board (EB) meeting, scheduled for 3-8 February 2020, will see discussions grouped for the first time ever around the three key pillars of the WHO Global Plan of Work for 2019-2023, including expanding health and wellbeing, protection from health emergencies, and universal health coverage to one billion more people. […] Continue reading -> “Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> New Drug Transparency Observatory Launched In France 13/06/2019 David Branigan Following the adoption of the World Health Assembly resolution on the transparency of medicines markets last month, a new civil society group has formed in France to monitor the French government’s implementation of the resolution. L’Observatoire Transparence Médicaments (Drug Transparency Observatory), was launched today in a statement calling on the French government and all countries […] Continue reading -> Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> WHA Strengthens Benefit Sharing System For Pandemic Flu Vaccine Development 03/06/2019 Catherine Saez In a little-publicised move, the WHA last week agreed to close a critical loophole in the WHO Pandemic Influenza Preparedness (PIP) Framework that could have allowed commercial vaccine manufacturers to indirectly make use of biological information about flu strains from another country – without providing that country with any benefits from the vaccines or antivirals […] Continue reading -> WHO’s EB Considers New Ways To Work With NGOs – Some Countries Criticise Activists’ Role At WHA 72 30/05/2019 Elaine Ruth Fletcher In the wake of a World Health Assembly that became a focus of intense activist and social media attention over a WHO resolution on medicines price transparency, member states are now looking at new rules for shaping involvement of NGOs and other “non-state actors” at public WHO meetings. Image Credits: WHO. Continue reading -> Posts navigation Older postsNewer posts
Access To Medicines Postponed; UHC, NTDs & Intellectual Property Feature In Next WHO Executive Board Agenda 14/11/2019 Elaine Ruth Fletcher WHO’s agenda for the next Executive Board (EB) meeting, scheduled for 3-8 February 2020, will see discussions grouped for the first time ever around the three key pillars of the WHO Global Plan of Work for 2019-2023, including expanding health and wellbeing, protection from health emergencies, and universal health coverage to one billion more people. […] Continue reading -> “Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> New Drug Transparency Observatory Launched In France 13/06/2019 David Branigan Following the adoption of the World Health Assembly resolution on the transparency of medicines markets last month, a new civil society group has formed in France to monitor the French government’s implementation of the resolution. L’Observatoire Transparence Médicaments (Drug Transparency Observatory), was launched today in a statement calling on the French government and all countries […] Continue reading -> Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> WHA Strengthens Benefit Sharing System For Pandemic Flu Vaccine Development 03/06/2019 Catherine Saez In a little-publicised move, the WHA last week agreed to close a critical loophole in the WHO Pandemic Influenza Preparedness (PIP) Framework that could have allowed commercial vaccine manufacturers to indirectly make use of biological information about flu strains from another country – without providing that country with any benefits from the vaccines or antivirals […] Continue reading -> WHO’s EB Considers New Ways To Work With NGOs – Some Countries Criticise Activists’ Role At WHA 72 30/05/2019 Elaine Ruth Fletcher In the wake of a World Health Assembly that became a focus of intense activist and social media attention over a WHO resolution on medicines price transparency, member states are now looking at new rules for shaping involvement of NGOs and other “non-state actors” at public WHO meetings. Image Credits: WHO. Continue reading -> Posts navigation Older postsNewer posts
“Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> New Drug Transparency Observatory Launched In France 13/06/2019 David Branigan Following the adoption of the World Health Assembly resolution on the transparency of medicines markets last month, a new civil society group has formed in France to monitor the French government’s implementation of the resolution. L’Observatoire Transparence Médicaments (Drug Transparency Observatory), was launched today in a statement calling on the French government and all countries […] Continue reading -> Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> WHA Strengthens Benefit Sharing System For Pandemic Flu Vaccine Development 03/06/2019 Catherine Saez In a little-publicised move, the WHA last week agreed to close a critical loophole in the WHO Pandemic Influenza Preparedness (PIP) Framework that could have allowed commercial vaccine manufacturers to indirectly make use of biological information about flu strains from another country – without providing that country with any benefits from the vaccines or antivirals […] Continue reading -> WHO’s EB Considers New Ways To Work With NGOs – Some Countries Criticise Activists’ Role At WHA 72 30/05/2019 Elaine Ruth Fletcher In the wake of a World Health Assembly that became a focus of intense activist and social media attention over a WHO resolution on medicines price transparency, member states are now looking at new rules for shaping involvement of NGOs and other “non-state actors” at public WHO meetings. Image Credits: WHO. Continue reading -> Posts navigation Older postsNewer posts
Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> New Drug Transparency Observatory Launched In France 13/06/2019 David Branigan Following the adoption of the World Health Assembly resolution on the transparency of medicines markets last month, a new civil society group has formed in France to monitor the French government’s implementation of the resolution. L’Observatoire Transparence Médicaments (Drug Transparency Observatory), was launched today in a statement calling on the French government and all countries […] Continue reading -> Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> WHA Strengthens Benefit Sharing System For Pandemic Flu Vaccine Development 03/06/2019 Catherine Saez In a little-publicised move, the WHA last week agreed to close a critical loophole in the WHO Pandemic Influenza Preparedness (PIP) Framework that could have allowed commercial vaccine manufacturers to indirectly make use of biological information about flu strains from another country – without providing that country with any benefits from the vaccines or antivirals […] Continue reading -> WHO’s EB Considers New Ways To Work With NGOs – Some Countries Criticise Activists’ Role At WHA 72 30/05/2019 Elaine Ruth Fletcher In the wake of a World Health Assembly that became a focus of intense activist and social media attention over a WHO resolution on medicines price transparency, member states are now looking at new rules for shaping involvement of NGOs and other “non-state actors” at public WHO meetings. Image Credits: WHO. Continue reading -> Posts navigation Older postsNewer posts
New Drug Transparency Observatory Launched In France 13/06/2019 David Branigan Following the adoption of the World Health Assembly resolution on the transparency of medicines markets last month, a new civil society group has formed in France to monitor the French government’s implementation of the resolution. L’Observatoire Transparence Médicaments (Drug Transparency Observatory), was launched today in a statement calling on the French government and all countries […] Continue reading -> Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> WHA Strengthens Benefit Sharing System For Pandemic Flu Vaccine Development 03/06/2019 Catherine Saez In a little-publicised move, the WHA last week agreed to close a critical loophole in the WHO Pandemic Influenza Preparedness (PIP) Framework that could have allowed commercial vaccine manufacturers to indirectly make use of biological information about flu strains from another country – without providing that country with any benefits from the vaccines or antivirals […] Continue reading -> WHO’s EB Considers New Ways To Work With NGOs – Some Countries Criticise Activists’ Role At WHA 72 30/05/2019 Elaine Ruth Fletcher In the wake of a World Health Assembly that became a focus of intense activist and social media attention over a WHO resolution on medicines price transparency, member states are now looking at new rules for shaping involvement of NGOs and other “non-state actors” at public WHO meetings. Image Credits: WHO. Continue reading -> Posts navigation Older postsNewer posts
Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> WHA Strengthens Benefit Sharing System For Pandemic Flu Vaccine Development 03/06/2019 Catherine Saez In a little-publicised move, the WHA last week agreed to close a critical loophole in the WHO Pandemic Influenza Preparedness (PIP) Framework that could have allowed commercial vaccine manufacturers to indirectly make use of biological information about flu strains from another country – without providing that country with any benefits from the vaccines or antivirals […] Continue reading -> WHO’s EB Considers New Ways To Work With NGOs – Some Countries Criticise Activists’ Role At WHA 72 30/05/2019 Elaine Ruth Fletcher In the wake of a World Health Assembly that became a focus of intense activist and social media attention over a WHO resolution on medicines price transparency, member states are now looking at new rules for shaping involvement of NGOs and other “non-state actors” at public WHO meetings. Image Credits: WHO. Continue reading -> Posts navigation Older postsNewer posts
WHA Strengthens Benefit Sharing System For Pandemic Flu Vaccine Development 03/06/2019 Catherine Saez In a little-publicised move, the WHA last week agreed to close a critical loophole in the WHO Pandemic Influenza Preparedness (PIP) Framework that could have allowed commercial vaccine manufacturers to indirectly make use of biological information about flu strains from another country – without providing that country with any benefits from the vaccines or antivirals […] Continue reading -> WHO’s EB Considers New Ways To Work With NGOs – Some Countries Criticise Activists’ Role At WHA 72 30/05/2019 Elaine Ruth Fletcher In the wake of a World Health Assembly that became a focus of intense activist and social media attention over a WHO resolution on medicines price transparency, member states are now looking at new rules for shaping involvement of NGOs and other “non-state actors” at public WHO meetings. Image Credits: WHO. Continue reading -> Posts navigation Older postsNewer posts
WHO’s EB Considers New Ways To Work With NGOs – Some Countries Criticise Activists’ Role At WHA 72 30/05/2019 Elaine Ruth Fletcher In the wake of a World Health Assembly that became a focus of intense activist and social media attention over a WHO resolution on medicines price transparency, member states are now looking at new rules for shaping involvement of NGOs and other “non-state actors” at public WHO meetings. Image Credits: WHO. Continue reading -> Posts navigation Older postsNewer posts